# Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

> **NCT00944905** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 46 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Non-hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** MDX-1203

## Key facts

- **NCT ID:** NCT00944905
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00944905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00944905, "Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00944905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*